



J. Serb. Chem. Soc. 86 (2) S32–S43 (2021)

SUPPLEMENTARY MATERIAL TO
**Molecular docking study on biomolecules isolated from
endophytic fungi**

JANKO IGNJATOVIĆ¹, NEVENA ĐAJIĆ¹, JOVANA KRMAR¹, ANA PROTIĆ¹,
BORUT ŠTRUKELJ² and BILJANA OTAŠEVIĆ^{1*}

¹Department of Drug Analysis, University of Belgrade – Faculty of Pharmacy, Vojvode Stepe 450, 11221 Belgrade, Serbia and ²Faculty of Pharmacy, University of Ljubljana, Aškerčeva cesta 7, 1000 Ljubljana, Slovenia

J. Serb. Chem. Soc. 86 (2) (2021) 125–137

TABLE S-I. Crystal and experimental data for molecular complexes with 1F0K receptor

Tested ligand	Free binding energy, kcal/mol	Ligand efficiency, kcal/mol	Inhibition constant, μ M	Intermolar energy, kcal/mol	VdW HB		Electrostatic energy, kcal/mol	Total internal, kcal/mol	Torsional energy, kcal/mol	Unbound energy, kcal/mol	<i>RMSD</i>	Mean binding energy, kcal/mol	Hydrogen bonds
					desolvation energy, kcal/mol	energy, kcal/mol							
Ampicillin*	-6.47	-0.27	18.08	-8.26	-6.50	-1.76	-2.95	1.79	-2.95	5.08	-6.09	Ampicilin:0:1:H Ampicilin:0:1:H	
325-3	-5.14	-0.23	172.04	-8.42	-7.94	-0.48	-2.30	3.28	-2.30	3.72	-3.85	325-3:0:1:H; 325-3:0:1:H; 1f0k:A:GLN289:HE22	

* Corresponding author. E-mail: biljana.otasevic@pharmacy.bg.ac.rs

S32

325-5	-4.78	-0.22	313.49	-7.76	-7.35	-0.41	-1.14	2.98	-1.14	3.72	-3.99	325-5:0:1:H; 1f0k:A:THR266:HN 1f0k:A:THR266:HG1; 1f0k:A:GLN289:HE22
CurvularideA	-4.76	-0.20	324.52	-9.23	-9.02	-0.21	-2.48	4.47	-2.48	6.17	-4.37	1f0k:A:LEU265:HN: Civularide-A:0:1:O Cuvularide-A:0:1H: 1f0k:A:SER192:OG 1f0k:A:GLN193:HN: Cuvularide-A:0:1:O 1f0k:A:GLN289:HE22 Cuvularide-A:0:1:O 1f0k:A:GLN289:HE22
CurvularideB	-4.10	-0.18	994.76	-7.68	-7.54	-0.14	-1.85	3.58	-1.85	6.79	-2.85	1f0k:A:GLN289:HE22
CurvularideC	-4.70	-0.20	361.64	-8.87	-8.52	-0.35	-2.97	4.18	-2.97	4.74	-3.55	Cuvularide-C:0 1:H; Cuvularide-C:0 1:H
CurvularideD	-4.74	-0.21	334.92	-8.02	-8.08	0.06	-0.81	3.28	-0.81	6.42	-3.81	1f0K:A:LEU265:HN
CurvularideE	-4.73	-0.21	343.80	-7.71	-7.52	-0.19	-1.79	2.98	-1.79	4.90	-3.91	Cuvularide-E: 0: 1:H; Cuvularide-E: 0: 1:H
Phomoenamamide	-4.97	-0.25	227.74	-7.65	-7.38	-0.27	-2.25	2.68	-2.25	4.46	-3.66	Phomoenamamide:0: 1:H; 1f0k:A:THR266:HN 1f0k:A:THR266:HG1
Compound 6	-3.88	-0.35	1430	-4.48	-4.37	-0.11	-0.27	0.60	-0.27	7.35	-3.73	1f0h:A:LEU265:HN: Compound_6:0: 1:O 1f0k:A:THR266:HN: Compound_6:0: 1:O
Compound 7	-4.56	-0.33	454.39	-5.45	-4.97	-0.48	-0.18	0.89	-0.18	5.83	-4.32	1f0k:A:ARG164:HH11: Compound_7:0: 1:O 1f0k:A:THR266:HN: Compound_7:0: 1:O

Phomol	-5.75	-0.20	60.52	-9.33	-9.14	-0.19	-4.48	3.58	-4.48	3.26	-4.95	Phomol:0: 1:H: 1f0k:A:GLY190:O Phomol:0: 1:H: 1f0k:A:GLY190:O 1f0k:A:GLN193:HN: Phomol:0: 1:O
Phomonitro- ester	-4.81	-0.28	296.63	-7.20	-5.96	-1.24	-0.33	2.39	-0.33	5.89	-4.37	Phomonitroester:0: 1:H: 1f0k:A:GLU269:OE2 1f0k:A:GLN289:HE22: Phomonitroester:0: 1:O,O

*Control ligand

TABLE S-II. Crystal and experimental data for molecular complexes with 3G7B receptor

Tested ligand	Free binding energy, kcal/mol	Ligand efficiency, kcal/mol	Inhibition constant, μ M	Intermolar energy, kcal/mol	VdW HB desolvation energy, kcal/mol	Electrostatic energy, kcal/mol	Total internal, kcal/mol	Torsional energy, kcal/mol	Unbound energy, kcal/mol	RMSD	Mean binding Energy, kcal/mol	Hydrogen bonds
Ampicillin*	-6.10	-0.25	33.93	-7.89	-5.25	-2.63	-1.71	1.79	1.71	5.77	-5.63	Ampicilin:0: 1:H: 3G7B:B:ASP53:OD1 Ampicilin:0: 1:H: 3G7B:B:GLU50:OE1 Ampicilin:0: 1:H: 3G7B:B:GLU50:OE1
325-3	-5.27	-0.24	135.56	-8.55	-7.83	-0.72	-2.26	3.28	-2.26	5.04	-4.50	325-3:0: 1:H: 3G7B:N:ASP57:OD2 325-3:0: 1:H: 3G7B:N:ASP57:OD2 3G7B:B:ASN54:HD21: 325-3:0 1:O 3G7B:B:VAL131:HN:

325-5	-4.60	-0.21	425.42	-7.58	-7.42	-0.16	-1.58	2.98	-1.58	3.92	-3.74	325-3:0 1:O 325-5:0 :1:H: 3G7B:B:ASP57:OD2 3G7B:B:VAL131:HN: 325-5:0 1:O 3G7B:B:ASN54:HD21:
CurvularideA	-2.58	-0.11	12930	-7.05	-6.30	-0.75	-3.36	4.47	-3.36	4.21	-0.86	325-5:0: 1:O Cuvularide-A:0: 1:H: 3G7B:B:ASP53:OD1 Cuvularide-A:0: 1:H: 3G7B:B:ASP53:OD1 Cuvularide-A:0: 1:H: 3G7B:B:GLU50:OE2 Cuvularide-A:0: 1:H: 3G7B:B:ASN54:OD1
CurvularideB	-4.36	-0.19	632.03	-7.94	-7.31	-0.64	-1.85	3.58	-1.85	3.98	-3.34	Cuvularide-B:0 1:H: 3G7B:B:GLU50:OE1 Cuvularide-B:0 1:H: 3G7B:B:GLU50:OE1 3g7B:B:HIS46:HE2: Cuvularide-B:0 1:O
CurvularideC	-3.21	-0.13	4440	-7.39	-6.72	-0.67	-0.62	4.18	-0.62	4.50	-1.79	Cuivularide-C:0: 1:H: 3G7B:B:ASP57:OD2 Cuivularide-C:0: 1:H: 3G7B:B:ASP57:OD1 Cuivularide-C:0: 1:H: 3G7B:B:ASP57:OD2
CurvularideD	-4.51	-0.20	495.24	-7.79	-7.63	-0.16	-1.24	3.28	-1.24	4.19	-3.34	Cuvularide-D:0: 1:H: 3G7B:ASP53:O 3G7B:B:ASN54:HD21: Cuvularide-D:0: 1:O 3G7B:B:VAL131:HN:

CurvularideE	-4.47	-0.19	532.45	-7.45	-7.36	-0.09	-1.01	2.98	-1.01	4.15	-3.54	Cuvularide-D:0: 1:O Cuvularide-E:0: 1:H: 3G7B:B:ASP52:OD1 3G7B:B:ASN54:HD21:
Phomoenamide	-4.64	-0.23	397.98	-7.32	-6.76	-0.56	-2.44	2.68	-2.44	3.27	-3.40	Cuvularide-E:0: 1:O 3G7B:B:ASN54:HD21: Phomoenamide:0: 1:O Phomoenamide:0: 1:H: 3G7B:B:GLU50:OE2 Phomoenamide:0: 1:H: 3G7B:B:GLU50:OE1 Phomoenamide:0: 1:H: 3G7B:B:GLU50:OE1 3g7b:B:VAL131:HN: Compound_6:0 1:O 3g7b:B:ASN54:HD21: Compound_6:0 1:O Compound_6:0 1:H: 3g7b:B:GLU50:OE2
Compound 6	-3.75	-0.34	1790	-4.35	-4.08	-0.27	0.05	0.6	0.05	6.72	-3.37	3g7b:B:ASN54:HD21: Compound_6:0 1:O Compound_6:0 1:H: 3g7b:B:GLU50:OE2
Compound 7	-4.20	-0.30	838.08	-5.09	-4.83	-0.26	0.15	0.89	0.15	4.80	-3.79	3g7b:B:ASN54:HD21: Compound:7:0 1:O 3g7b:B:VAL131:HN: Compound_7:0: 1:O
Phomol	-3.74	-0.13	1800	-7.32	-7.14	-0.19	-3.51	3.58	-3.51	4.89	-2.43	Phomol:0 1:H: 3g7b:B:ASP53:OD2 3g7b:B:ASN206:HD22: Phomol:0 1:O

Phomonitroester	-3.88	-0.23	1440	-6.26	-6.25	-0.01	-0.41	2.39	-0.41	6.80	-3.05	3g7b:B:VAL130:HN: Phomonitroester:0:1:O Phomonitroester:0:1:H: 3g7b:B:GLU50:OE1 3g7b:B:HIS46:HE2: Phomonitroester:0:1:O 3g7b:B:VAL131:HN: Phomonitroester:0:1:O,O
-----------------	-------	-------	------	-------	-------	-------	-------	------	-------	------	-------	--

*Control ligand

TABLE S-III. Crystal and experimental data for molecular complexes with ISHV receptor

Tested ligand	Free binding energy, kcal/mol	Ligand efficiency, kcal/mol	Inhibition constant, μ M	Intermolar energy, kcal/mol	VdW HB desolvation energy, kcal/mol	Electrostatic energy, kcal/mol	Total internal, kcal/mol	Torsional energy, kcal/mol	Unbound energy, kcal/mol	RMSD	Mean binding Energy, kcal/mol	Hydrogen bonds
Ampicillin*	-1.90	0.08	40320	-3.69	-2.40	-1.29	-3.09	1.79	-3.09	5.08	-1.82	1shv:A:ARG205:HH21
325-3	0.33	0.02	N.A.	-2.95	-2.86	-0.09	-4.75	3.28	-4.75	7.26	1.09	1shv:A:ARG205:HH21
325-5	-1.79	-0.08	48870	-4.77	-4.40	-0.37	-2.19	2.98	-2.19	5.65	-1.30	1shv:A:ARG202:HE; 1shv:A:ARG202:HH21 1shv:A:ARG205:HH21
CurvularideA	-0.41	-0.02	497240	-4.89	-4.68	-0.21	-5.60	4.47	-5.60	5.07	0.91	1shv:A:ARG202:HE
CurvularideB	-0.92	-0.04	210410	-4.50	-4.21	-0.29	-1.96	3.58	-1.96	7.41	-0.17	1shv:A:ARG202:HE; 1shv:A:ARG205:HE 1shv:A:ARG205:HH21
CurvularideC	0.75	0.03	N.A.	-3.43	-3.29	-0.14	-5.10	4.18	-5.10	4.74	1.45	None
CurvularideD	-1.57	-0.07	70350	-4.85	-4.47	-0.38	-2.01	3.28	-2.01	6.97	-0.79	1shv:A_ARG202:HE; 1shv:A_ARG205:HH21
CurvularideE	-1.27	-0.06	116590	-4.26	-3.90	-0.36	-2.87	2.98	-2.87	5.05	-0.53	1shv:A:ARG202:HE; 1shve:A:ARG205:HE 1shv:A:ARG205:HH21

Phomoenamide	-1.78	-0.09	49500	-4.47	-4.13	-0.33	-4.23	2.68	-4.23	6.51	-0.91	Phomoenamide:0: 1:H
Compound 6	-2.48	-0.23	15230	-3.08	-2.75	-0.33	-0.41	0.60	-0.41	7.48	-2.32	1shv:A:ARG202:HE: Compound_6:0: 1:O 1shv:A:ARG205:HE: Compound_6:0: 1:O
Compound 7	-2.85	-0.20	8100	-3.75	-3.43	-0.32	-0.21	0.89	-0.21	5.97	-2.67	1shv:A:ARG202:HH21: Compound_7:0: 1:O 1shv:A:ARG205:HE: Compound_7:0: 1:O 1shv:A:ARG205:HH21: Compound_7:0: 1:O 1shv:A:ARG202:HE: Compound_7:0: 1:O
Phomol	-0.55	0.02	395820	-4.13	-3.89	-4.13	-4.47	3.58	-4.47	5.28	-0.17	1shv:A:ARG202:HH21: Phomol:0: 1:O 1shv:A:ARG205:HH21: Phomol:0: 1:O
Phomonitroester	-2.67	-0.16	11060	-5.06	-3.70	-1.35	-0.57	2.39	-0.57	7.46	-2.13	1shv:A:ARG202:HH21: Phomonitroester:0: 1:O 1shv:A:ARG205:HH21: Phomonitroester:0: 1:O 1shv:A:ARG205:HE: Phomonitroester:0: 1:O 1shv:A:ARG202:HE: Phomonitroester:0: 1:O,O

* Control ligand

TABLE S-IV. Crystal and experimental data for molecular complexes with 3VSL receptor

Tested ligand	Free binding energy, kcal/mol	Ligand efficiency, kcal/mol	Inhibition constant, μ M	Intermolar energy, kcal/mol	VdW HB desolvatation energy, kcal/mol	Electrostatic energy, kcal/mol	Total internal, kcal/mol	Torsional energy, kcal/mol	Unbound energy, kcal/mol	RMSD	Mean binding Energy, kcal/mol	Hydrogen bonds
Ampicillin*	1.72	0.07	N.A.	-0.06	0.00	-0.06	-3.19	1.79	-3.19	5.36	1.73	None
325-3	3.27	0.15	N.A.	-0.01	0.00	-0.01	-6.12	3.28	-6.12	4.94	3.27	None
325-5	2.98	0.14	N.A.	-0.01	0.00	-0.01	-3.85	2.98	-3.85	5.16	2.98	None
CurvularideA	4.47	0.19	N.A.	-0.01	0.00	-0.01	-6.97	4.47	-6.97	3.74	4.47	None
CurvularideB	3.57	0.16	N.A.	-0.01	0.00	-0.01	-2.94	3.58	-2.94	6.16	3.57	None
CurvularideC	4.17	0.17	N.A.	-0.01	0.00	-0.01	-5.73	4.18	-5.73	4.50	4.17	None
CurvularideD	3.27	0.14	N.A.	-0.01	0.00	-0.01	-2.47	3.28	-2.47	4.85	3.28	None
CurvularideE	2.98	0.13	N.A.	-0.01	0.00	-0.01	-3.32	2.98	-3.32	4.60	2.98	None
Phomoenamides	2.68	0.13	N.A.	-0.01	0.00	-0.01	-5.61	2.68	-5.61	6.41	2.68	None
Compound 6	0.59	0.05	N.A.	0.00	0.00	0.00	-0.57	0.60	-0.57	7.59	0.59	None
Compound 7	0.89	0.06	N.A.	-0.01	0.00	-0.01	-0.46	0.89	-0.46	6.34	0.89	None
Phomol	3.57	0.12	N.A.	-0.01	0.00	-0.01	-5.51	3.58	-5.51	4.84	3.57	None
Phomonitroester	2.05	0.12	N.A.	-0.34	0.00	-0.34	-2.37	2.39	-2.37	8.34	2.06	None

*Control ligand

TABLE S-V. Crystal and experimental data for molecular complexes with 4EMV receptor

Tested ligand	Free binding energy, kcal/mol	Ligand efficiency, kcal/mol	Inhibition constant, μ M	Intermolar energy, kcal/mol	VdW HB desolvatation energy, kcal/mol	Electrostatic energy, kcal/mol	Total internal, kcal/mol	Torsional energy, kcal/mol	Unbound energy, kcal/mol	RMSD	Mean binding Energy, kcal/mol	Hydrogen bonds
Ampicillin*	1.75	0.07	N.A.	-0.04	0.00	-0.04	-3.19	1.79	-3.19	5.34	1.76	None
325-3	3.28	0.15	N.A.	0.00	0.00	0.00	-5.89	3.28	-5.89	5.31	3.28	None
325-5	2.98	0.14	N.A.	0.00	0.00	0.00	-3.80	2.98	-3.80	6.54	2.98	None
CurvularideA	4.47	0.19	N.A.	0.00	0.00	0.00	-6.94	4.47	-6.94	4.37	4.47	None
CurvularideB	3.58	0.16	N.A.	0.00	0.00	0.00	-2.93	3.58	-2.93	6.32	3.58	None
CurvularideC	4.17	0.17	N.A.	0.00	0.00	0.00	-5.70	4.18	-5.70	3.93	4.17	None
CurvularideD	3.28	0.14	N.A.	0.00	0.00	0.00	-2.48	3.28	-2.48	5.63	3.28	None
CurvularideE	2.98	0.13	N.A.	0.00	0.00	0.00	-3.31	2.98	-3.31	5.38	2.98	None
Phomoenamide	2.68	0.13	N.A.	0.00	0.00	0.00	-5.60	2.68	-5.60	3.50	2.68	None
Compound 6	0.59	0.05	N.A.	0.00	0.00	0.00	-0.57	0.60	-0.57	8.42	0.59	None
Compound 7	0.89	0.06	N.A.	0.00	0.00	0.00	-0.46	0.89	-0.46	6.24	0.89	None
Phomol	3.58	0.12	N.A.	0.00	0.00	0.00	-5.49	0.00	-5.49	4.50	3.58	None
Phomonitroester	2.43	0.14	N.A.	0.04	0.00	0.04	-2.39	2.39	-2.39	8.77	2.43	None

* Control ligand

TABLE S-VI. Crystal and experimental data for molecular complexes with 1JJJ receptor

Tested ligand	Free binding energy, kcal/mol	Ligand efficiency, kcal/mol	Inhibition constant, μ M	Intermolar energy, kcal/mol	VdW HB desolvatation energy, kcal/mol	Electrostatic energy, kcal/mol	Total internal, kcal/mol	Torsional energy, kcal/mol	Unbound energy, kcal/mol	RMSD	Mean binding Energy, kcal/mol	Hydrogen bonds
Ampicillin*	1.78	0.07	N.A.	-0.01	0.00	-0.01	-3.20	1.79	-3.20	4.28	1.78	None
325-3	3.28	0.15	N.A.	0.00	0.00	0.00	-6.15	3.28	-6.15	3.10	3.28	None
325-5	2.98	0.14	N.A.	0.00	0.00	0.00	-3.73	2.98	-3.73	2.92	2.98	None
CurvularideA	4.47	0.19	N.A.	0.00	0.00	0.00	-6.88	4.47	-6.88	3.88	4.47	None
CurvularideB	3.58	0.16	N.A.	0.00	0.00	0.00	-2.94	3.58	-2.94	3.94	3.58	None
CurvularideC	4.18	0.17	N.A.	0.00	0.00	0.00	-5.74	4.18	-5.74	2.67	4.18	None
CurvularideD	3.28	0.14	N.A.	0.00	0.00	0.00	-2.47	3.28	-2.47	6.52	3.28	None
CurvularideE	2.98	0.13	N.A.	0.00	0.00	0.00	-3.31	2.98	-3.31	3.84	2.98	None
Phomoenamamide	2.68	0.13	N.A.	0.00	0.00	0.00	-5.61	2.68	-5.61	3.68	2.68	None
Compound 6	0.60	0.05	N.A.	0.00	0.00	0.00	-0.57	0.60	-0.57	6.10	0.60	None
Compound 7	0.89	0.06	N.A.	0.00	0.00	0.00	-0.46	0.89	-0.46	2.45	0.89	None
Phomol	3.58	0.12	N.A.	0.00	0.00	0.00	-5.51	3.58	-5.51	2.61	3.58	None
Phomonitroester	2.46	0.14	N.A.	0.08	0.00	0.08	-2.38	2.39	-2.38	8.62	2.47	None

*Control ligand

TABLE S-VII. Crystal and experimental data for molecular complexes with 1KZN receptor

Tested ligand	Free binding energy, kcal/mol	Ligand efficiency, kcal/mol	Inhibition constant, μ M	Intermolar energy, kcal/mol	VdW HB desolvatation energy, kcal/mol	Electrostatic energy, kcal/mol	Total internal, kcal/mol	Torsional energy, kcal/mol	Unbound energy, kcal/mol	RMSD	Mean binding Energy, kcal/mol	Hydrogen bonds
Ampicillin*	1.78	0.07	N.A.	-0.01	0.00	-0.01	-3.20	1.79	-3.20	7.86	1.78	None
325-3	3.28	0.15	N.A.	0.00	0.00	0.00	-6.16	3.28	-6.16	4.60	3.28	None
325-5	2.98	0.14	N.A.	0.00	0.00	0.00	-3.65	2.98	-3.65	5.58	2.98	None
CurvularideA	4.47	0.19	N.A.	0.00	0.00	0.00	-6.83	4.47	-6.83	6.28	4.47	None
CurvularideB	3.58	0.16	N.A.	0.00	0.00	0.00	-2.94	3.58	-2.94	3.13	3.58	None
CurvularideC	4.18	0.17	N.A.	0.00	0.00	0.00	-5.76	4.18	-5.76	2.45	4.18	None
CurvularideD	3.28	0.14	N.A.	0.00	0.00	0.00	-2.48	3.28	-2.48	5.24	3.28	None
CurvularideE	2.99	0.13	N.A.	0.00	0.00	0.00	-3.32	2.98	-3.32	4.29	2.98	None
Phomoenamide	2.68	0.13	N.A.	0.00	0.00	0.00	-5.61	2.68	-5.61	6.11	2.68	None
Compound 6	0.60	0.05	N.A.	0.00	0.00	0.00	-0.57	0.60	-0.57	7.32	0.60	None
Compound 7	0.89	0.06	N.A.	0.00	0.00	0.00	-0.46	0.89	-0.46	7.31	0.89	None
Phomol	3.58	0.12	N.A.	0.00	0.00	0.00	-5.49	3.58	-5.49	2.86	3.58	None
Phomonitroester	2.43	0.14	N.A.	0.05	0.00	0.05	-2.38	2.39	-2.38	8.21	2.43	None

*Control ligand

TABLE S-VIII. Crystal and experimental data for molecular complexes with 3K3P receptor

Tested ligand	Free binding energy, kcal/mol	Ligand efficiency, kcal/mol	Inhibition constant, μ M	Intermolar energy, kcal/mol	VdW HB desolvatation energy, kcal/mol	Electrostatic energy, kcal/mol	Total internal, kcal/mol	Torsional energy, kcal/mol	Unbound energy, kcal/mol	RMSD	Mean binding Energy, kcal/mol	Hydrogen bonds
Ampicillin*	1.75	0.07	N.A.	-0.04	0.00	-0.04	-3.20	1.79	-3.20	5.97	1.76	None
325-3	3.28	0.15	N.A.	0.00	0.00	0.00	-6.11	3.28	-6.11	4.12	3.28	None
325-5	2.98	0.14	N.A.	-0.01	0.00	-0.01	-3.70	2.98	-3.70	3.80	2.98	None
CurvularideA	4.47	0.19	N.A.	0.00	0.00	0.00	-6.87	4.47	-6.87	5.19	4.47	None
CurvularideB	3.58	0.16	N.A.	0.00	0.00	0.00	-2.93	3.58	-2.93	5.82	3.58	None
CurvularideC	4.17	0.17	N.A.	0.00	0.00	0.00	-5.67	4.18	-5.67	2.98	4.17	None
CurvularideD	3.28	0.14	N.A.	0.00	0.00	0.00	-2.47	3.28	-2.47	5.11	3.28	None
CurvularideE	2.98	0.13	N.A.	0.00	0.00	0.00	-3.30	2.98	-3.30	3.58	2.98	None
Phomoenamide	2.68	0.13	N.A.	0.00	0.00	0.00	-5.62	2.68	-5.62	5.59	2.68	None
Compound 6	0.60	0.05	N.A.	0.00	0.00	0.00	-0.57	0.60	-0.57	6.15	0.60	None
Compound 7	0.89	0.06	N.A.	0.00	0.00	0.00	-0.46	0.89	-0.46	5.47	0.89	None
Phomol	3.58	0.12	N.A.	0.00	0.00	0.00	-5.53	3.58	-5.53	3.16	3.58	None
Phomonitroester	2.58	0.15	N.A.	0.19	0.00	0.19	-2.37	-2.37	-2.37	9.17	2.58	None

*Control ligand